Valneva receives ema's positive chmp opinion for its chikungunya vaccine

Saint herblain (france), may 31, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has adopted a positive opinion recommending authorization of valneva's single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.
VALN Ratings Summary
VALN Quant Ranking